- Home
- HALO vs ROIV Comparison
HALO vs ROIV Comparison
Compare HALO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HALO
- ROIV
- Stock Information
- Founded
- HALO 1998
- ROIV 2014
- Country
- HALO United States
- ROIV United Kingdom
- Employees
- HALO N/A
- ROIV N/A
- Industry
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- HALO Health Care
- ROIV Health Care
- Exchange
- HALO Nasdaq
- ROIV Nasdaq
- Market Cap
- HALO 7.4B
- ROIV 7.8B
- IPO Year
- HALO N/A
- ROIV N/A
- Fundamental
- Price
- HALO $56.07
- ROIV $10.99
- Analyst Decision
- HALO Buy
- ROIV Buy
- Analyst Count
- HALO 9
- ROIV 4
- Target Price
- HALO $63.56
- ROIV $17.50
- AVG Volume (30 Days)
- HALO 3.5M
- ROIV 5.1M
- Earning Date
- HALO 05-06-2025
- ROIV 05-29-2025
- Dividend Yield
- HALO N/A
- ROIV N/A
- EPS Growth
- HALO 55.40
- ROIV N/A
- EPS
- HALO 3.76
- ROIV N/A
- Revenue
- HALO $1,084,306,000.00
- ROIV $29,053,000.00
- Revenue This Year
- HALO $25.77
- ROIV N/A
- Revenue Next Year
- HALO $18.01
- ROIV N/A
- P/E Ratio
- HALO $14.92
- ROIV N/A
- Revenue Growth
- HALO 25.64
- ROIV N/A
- 52 Week Low
- HALO $42.01
- ROIV $8.73
- 52 Week High
- HALO $70.51
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- HALO 48.34
- ROIV 52.59
- Support Level
- HALO $54.00
- ROIV $10.59
- Resistance Level
- HALO $55.25
- ROIV $11.37
- Average True Range (ATR)
- HALO 2.53
- ROIV 0.32
- MACD
- HALO 0.14
- ROIV -0.01
- Stochastic Oscillator
- HALO 42.01
- ROIV 52.23
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.